By Dividend Growth Investor : Most readers are probably aware that it has been getting more difficult to find decent values in the current environment. When I ran my screens for valuation, I stumbled upon AT&T (NYSE: T ) and Verizon (NYSE: VZ ), which are telecom behemoths in the US. AT&T has ...
The FDA approves a label expansion for Janssen Biotech's ( JNJ -0.2% ) Imbruvica ( ibrutinib ) to include patients with chronic lymphocytic leukemia (CLL) who carry a 17p deletion , a
By Wall Street Playbook : With better-than-expected results coming in from AbbVie (NYSE: ABBV ), Johnson & Johnson ( NYSE : JNJ ) and other dominant names in Big Pharma, Merck (NYSE: MRK ) investors have raised the bar. They are demanding
deletion or TP53 mutation who are unsuitable for chemo-immunotherapy. Ibrutinib is being co-developed by Johnson & Johnson ( JNJ -0.2% ) unit Janssen-Cilag International NV and Pharmacyclics Switzerland GmbH. Once approved, Janssen
LONDON, July 25 (Reuters) - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a...
Balanced Investing : Bringing Sandra Peterson to turnaround the failing McNeil Consumer Healthcare division of Johnson & Johnson ( NYSE : JNJ ) has proven quite fruitful for the company. Although her strategic moves may have sounded abrupt at the beginning
Organovo (NYSEMKT: ONVO ) are up 17% premarket on robust volume in response the signing of a research agreement with Johnson & Johnson unit Janssen Research and Development to evaluate the use of 3D bio-printed tissue in drug discovery. Financial
in our valuation. With quarterly revenue growth of 1% in constant currency, Zimmer trailed rivals Stryker and Johnson & Johnson 's DePuy business. In recent quarters, Zimmer has benefited from the introduction of its new Persona knee. However
Balanced funds thread examined income builder funds and specifically Thornburg Income Builder. I'll let that rest. I sold JNJ recently when it topped 100 - had a great gain - love the company and the industry - but don't like the ~2.7 yield
a Phase 3 trial comparing a once-daily dose of Solzentry ( maraviroc ) ( PFE +0.7% ) with Prezista (darunavir) ( JNJ +1.1% ) and Norvir (ritonavir) ( ABBV +0.2% ) to emtricitabine / tenofir with darunavir plus ritonavir (DRV